Abstract
The current standard to assess pentavalent antimonial (SSG) susceptibility of Leishmania is a laborious in vitro assay of which the result has little clinical value because SSG-resistant parasites are also found in SSG-cured patients. Candidate genetic markers for clinically relevant SSG-resistant parasites identified by full genome sequencing were here validated on a larger set of clinical strains. We show that 3 genomic locations suffice to specifically detect the SSG-resistant parasites found only in patients experiencing SSG treatment failure. This finding allows the development of rapid assays to monitor the emergence and spread of clinically relevant SSG-resistant Leishmania parasites.
Original language | English |
---|---|
Journal | Journal of Infectious Diseases |
Volume | 206 |
Issue number | 5 |
Pages (from-to) | 752-755 |
Number of pages | 4 |
ISSN | 0022-1899 |
DOIs | |
Publication status | Published - 2012 |
Keywords
- Protozoal diseases
- Visceral
- Leishmaniasis
- Kala azar
- Leishmania donovani
- Vectors
- Sandflies
- Phlebotomus argentipes
- Drug resistance
- SSG
- Antimonials
- Treatment failure
- Genetic markers
- Genome sequencing
- Strains
- Haplotypes
- Identification
- Assays
- India
- Asia-South